Esketamine-Induced Dissociation: A Case Report.
Jake Scarcella, Jeffrey MacDaniels, Lucinda Coffin, Thomas Schwartz
Journal of Psychoactive Drugs November 10, 2024 DOI: 10.1080/02791072.2024.2424283 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | 41-year-old female with treatment-resistant depression |
| Intervention | Esketamine |
| Topics | Esketamine Ketamine |
| Keywords | Treatment-resistant depression trd Adverse effect ae #depression-treatment trd Therapy Antidepressant #esketamine ketamine #adverse-effects ae Side effects Drug reactions #dissociation dep |
| Citations | 1 |
| Key findings | A patient with treatment-resistant depression developed a severe dissociative episode with hallucinogenic-like phenomena while taking esketamine, despite significant improvement in depressive symptoms. |
Abstract
Esketamine, the isolated S-enantiomer of ketamine, has been a recent breakthrough as a non-monoaminergic treatment for treatment-resistant depression (TRD). This case report explores a rare adverse event in a 41-year-old female with TRD, who, despite experiencing significant depressive improvement with esketamine, encountered a severe dissociative episode accompanied by hallucinogenic-like phenomena. While esketamine's efficacy in TRD is well-documented, this pronounced dissociation should be taken into consideration by researchers and clinicians before prescribing. As esketamine continues to aid TRD treatment, comprehension of its safety profile becomes essential for informed decision-making, ensuring optimized patient care in the vast development of antidepressant therapies.
Comparable studies
Other case reports and case series on esketamine, most cited first.
Citations in the library
Cites 20
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial American Journal of Psychiatry August 28, 2013
- A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression Archives of General Psychiatry August 1, 2010
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study American Journal of Psychiatry May 21, 2019
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression JAMA Psychiatry June 5, 2019
and 15 more in the library